Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.1
3.0
Journals
JPM
Special Issues
Updates on Precision Medicine in Hematological Disorders
share announcement

Updates on Precision Medicine in Hematological Disorders

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Omics/Informatics".

Deadline for manuscript submissions: closed (30 July 2022) | Viewed by 4864

Special Issue Editor

Dr. Sergiu Pasca

E-Mail Website
Guest Editor
Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj Napoca, Romania
Interests: hematology; data analysis; next generation sequencing; bioinformatics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Due to the relative ease of sample acquirement and because of several technological advances, the field of hematology has seen a rapid growth in the implementation of personalized medicine. This has been especially true for the case of mutation profiling, with certain subtypes of hematological malignancies having specific management strategies. Additionally, because of the advances in transcriptomics, proteomics and metabolomics, it is possible for the field of hematology to further see advances in the direction of personalized medicine.

We are pleased to invite you to submit papers with results on basic and clinical research regarding the prediction of malignant cell biology or of clinical outcomes.

In this special issue, original research articles as well as reviews are welcome. Research areas may include, but are not limited to:

  • genetics/genomics of hematological malignancies
  • transcriptomics of hematological malignancies
  • proteomics of hematological malignancies
  • metabolomics of hematological malignancies
  • experimental data regarding hematological malignancies
  • the importance of the tumor microenvironment in hematological malignancies

We look forward to receiving your contributions.

Dr. Sergiu Pasca
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hematology
  • precision medicine
  • personalized medicine
  • mutations
  • molecular profiling
  • biomarkers

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

10 pages, 298 KiB  
Article
Identification of Genomic Variants Associated with the Risk of Acute Lymphoblastic Leukemia in Native Americans from Brazilian Amazonia
by Luciana P. C. Leitão, Darlen C. de Carvalho, Juliana C. G. Rodrigues, Marianne R. Fernandes, Alayde V. Wanderley, Lui W. M. S. Vinagre, Natasha M. da Silva, Lucas F. Pastana, Laura P. A. Gellen, Matheus C. E. Assunção, Sweny S. M. Fernandes, Esdras E. B. Pereira, André M. Ribeiro-Dos-Santos, João F. Guerreiro, Ândrea Ribeiro-dos-Santos, Paulo P. de Assumpção, Sidney E. B. dos Santos and Ney P. C. dos Santos
J. Pers. Med. 2022, 12(6), 856; https://doi.org/10.3390/jpm12060856 - 25 May 2022
Cited by 2 | Viewed by 1703
Abstract
A number of genomic variants related to native American ancestry may be associated with an increased risk of developing Acute Lymphoblastic Leukemia (ALL), which means that Latin American and hispanic populations from the New World may be relatively susceptible to this disease. However, [...] Read more.
A number of genomic variants related to native American ancestry may be associated with an increased risk of developing Acute Lymphoblastic Leukemia (ALL), which means that Latin American and hispanic populations from the New World may be relatively susceptible to this disease. However, there has not yet been any comprehensive investigation of the variants associated with susceptibility to ALL in traditional Amerindian populations from Brazilian Amazonia. We investigated the exomes of the 18 principal genes associated with susceptibility to ALL in samples of 64 Amerindians from this region, including cancer-free individuals and patients with ALL. We compared the findings with the data on populations representing five continents available in the 1000 Genomes database. The variation in the allele frequencies found between the different groups was evaluated using Fisher’s exact test. The analyses of the exomes of the Brazilian Amerindians identified 125 variants, seven of which were new. The comparison of the allele frequencies between the two Amerindian groups analyzed in the present study (ALL patients vs. cancer-free individuals) identified six variants (rs11515, rs2765997, rs1053454, rs8068981, rs3764342, and rs2304465) that may be associated with susceptibility to ALL. These findings contribute to the identification of genetic variants that represent a potential risk for ALL in Amazonian Amerindian populations and might favor precision oncology measures. Full article
(This article belongs to the Special Issue Updates on Precision Medicine in Hematological Disorders)

Review

Jump to: Research

14 pages, 1925 KiB  
Review
Mechanistic Insights in Hemophagocytic Lymphohistiocytosis: Subsequent Acute Hepatic Failure in a Multiple Myeloma Patient Following Therapy with Ixazomib-Lenalidomide-Dexamethasone
by Catalin Constantinescu, Bobe Petrushev, Ioana Rus, Horia Stefanescu, Otilia Frasinariu, Simona Margarit, Delia Dima and Ciprian Tomuleasa
J. Pers. Med. 2022, 12(5), 678; https://doi.org/10.3390/jpm12050678 - 23 Apr 2022
Cited by 2 | Viewed by 2828
Abstract
Hemophagocytic lymphohistiocytosis (HLH) is a rare, elusive, and life-threatening condition that is characterized by the pathologic and uncontrolled secondary activation of the cytotoxic T-cells, natural killer cells (NK-cells), and macrophages of the innate immune system. This condition can develop in sporadic or familial [...] Read more.
Hemophagocytic lymphohistiocytosis (HLH) is a rare, elusive, and life-threatening condition that is characterized by the pathologic and uncontrolled secondary activation of the cytotoxic T-cells, natural killer cells (NK-cells), and macrophages of the innate immune system. This condition can develop in sporadic or familial contexts associated with hematological malignancies, as a paraneoplastic syndrome, or linked to an infection related to immune system deficiency. This leads to the systemic inflammation responsible for the overall clinical manifestations. Diagnosis should be thorough, and treatment should be initiated as soon as possible. In the current manuscript, we focus on classifying the HLH spectrum, describing the pathophysiology and the tools needed to search for and correctly identify HLH, and the current therapeutic opportunities. We also present the first case of a multiple myeloma patient that developed HLH following therapy with the ixazomib-lenalidomide-dexamethasone protocol. Full article
(This article belongs to the Special Issue Updates on Precision Medicine in Hematological Disorders)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop